The use of GLP-1 receptor agonists is frequently associated with gastrointestinal adverse effects, particularly nausea, vomiting, diarrhea or constipation
or used for parenteral nutrition
Employer-sponsored self-funded: 22% weight-loss coverage probability Employer-sponsored fully insured: 38% weight-loss coverage probability Individual marketplace: 45% weight-loss coverage probability Question 2: Does your Summary Plan Description list weight-loss medication exclusions
These concerns highlight the necessity for ongoing treatment and monitoring during GLP-1 therapy to ensure sustainable weight loss while minimizing adverse outcomes, such as sarcopenia
About one-third to one-half of the carnitine was free carnitine and the remainder was acetylcarnitine
In its active form, known as GSH, glutathione neutralizes harmful free radicals and protects cells from damage